LQT017C1
NUIGi018-A
General
Cell Line |
|
| hPSCreg name | NUIGi018-A |
| Cite as: | NUIGi018-A (RRID:CVCL_WU41) |
| Alternative name(s) |
LQT017C1
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
NUIGi018-B (LQT017C3) NUIGi018-C (LQT017Cx) |
| Last update | 2nd March 2021 |
| User feedback | |
Provider |
|
| Generator | National University of Ireland Galway (NUIG) |
| Owner | National University of Ireland Galway (NUIG) |
| Derivation country | Ireland |
External Databases |
|
| Cellosaurus | CVCL_WU41 |
| BioSamples | SAMEA8325237 |
| Wikidata | Q98128167 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
No |
| Subclones | |
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 45-49 |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA5873404 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Research Ethics Committee of Galway University Hospitals |
| Approval number | C.A.750 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Research Ethics Committee of Galway University Hospitals |
| Approval number | C.A.750 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
Dermal fibroblasts are the major cell type in dermis and are commonly accepted as terminally differentiated cells.
|
| Age of donor (at collection) | 45-49 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
| Medium |
Essential 8™ Flex
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| Alkaline Phosphatase |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| SOX2 |
Yes |
|
||||
| NANOG |
Yes |
|
Differentiation Potency
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
LQT017C1 SNP
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Cell Line) |
|

Login to share your feedback, experiences or results with the research community.